Interestingly, miR181b sensitizes non-small cell lung cancer cells to chemotherapy by targeting directly TGFβR1/SMAD and indirectly PI3K/AKT pathway [41]. This evidence concerns the gene AKT1 and non-small cell lung carcinoma.